Sanford Burnham Prebys Medical Discovery Institute

Sanford Burnham Prebys Medical Discovery Institute, a nonprofit biomedical research organization based in La Jolla, California, operates as a prime recipient on federal research grants spanning cancer, aging, infectious disease, and neurological disorder research, with the National Institutes of Health and its component institutes—particularly the National Cancer Institute and National Institute on Aging—accounting for the plurality of recent awards across 36 distinct federal customer agencies. The institute does not hold federal contracts; it operates exclusively as a grant recipient (91% prime, 9% sub-recipient across its 696-award portfolio), competing in full-and-open federal grant programs rather than procurement vehicles.

Sanford Burnham Prebys' federal footprint centers on fundamental and translational biomedical research. Recent representative work includes a $1.33 million NIH grant investigating oxidative stress responses in altered gravity environments using Drosophila and C. elegans model organisms to support NASA spaceflight physiology research; a $2.9 million National Institute of General Medical Sciences award examining molecular mechanisms of nuclear pore complex formation and their role in cellular aging and neurodegenerative disease; a $670 thousand National Institute of Neurological Disorders and Stroke project characterizing voltage-gated potassium channel assembly in the brain; a $3.86 million Cooperative Agreement with NINDS to develop neurotensin receptor 1 allosteric modulators for pain and opioid use disorder, with sub-recipients at Duke University and the University of Minnesota; and a $1.6 million National Heart, Lung, and Blood Institute grant developing gene therapy for enhanced cardiac repair post-myocardial infarction. The institute's research portfolio emphasizes cancer metabolism, immune checkpoint mechanisms, aging and cellular senescence, pancreatic cancer therapeutics, and neurodegeneration. Recent work spans pancreatic cancer (collagen metabolism, pH homeostasis, metabolic interventions), Alzheimer's disease (APOE4 correctors, tau pathology, microglial dysfunction), immune-oncology (checkpoint blockade, viral mimicry approaches), and regenerative medicine (cardiac reprogramming, muscle stem cell biology).

Customer concentration sits heavily with NIH. The top five funders—NIH overall (275 awards), the National Cancer Institute (74 awards), the National Institute on Aging (62 awards), the Department of Defense (29 awards), and HHS broadly (28 awards)—account for 67% of awards by count. The National Aeronautics and Space Administration's Shared Services Center represents the highest potential-value customer at $2.5 million across 6 awards, reflecting the institute's spaceflight physiology research. The distribution reveals no significant conflict: NIH and its component institutes dominate both volume and dollars, with DoD providing secondary exposure.

Activity has remained relatively steady: 22 awards in 2023, 31 in 2024, 23 in 2025, and 22 in 2026, with one award recorded to date in 2027. Fifty-three awards face ultimate completion within the next twenty-four months, creating recompete opportunity across cancer biology, aging research, and drug discovery programs. Service Contract Inventory data shows minimal federal services engagement (4 SCI records, all as named subcontractor, yielding 9.7 FTEs in FY2022 and 2.0 FTEs in FY2024), confirming that Sanford Burnham Prebys' federal footprint rests on research grants rather than federal service delivery contracts. The institute passes funding to numerous sub-recipients including Duke University, the University of Minnesota, UCLA, UC Davis, Cold Spring Harbor Laboratory, and the La Jolla Institute for Immunology, positioning itself as a prime research anchor with a national collaborative network. Its role in the federal research ecosystem is that of a premier biomedical research institution competing for NIH research funding, not a federal contractor or service provider.